SLU-PP-332 250mcg BAM15 50mcg – 60 Tablets

Introduction to SLU-PP-332 + BAM15

This combination product leverages the complementary metabolic benefits of SLU-PP-332, an ERRα/β/γ agonist, and BAM15, a mitochondrial uncoupler, to target energy expenditure, fat oxidation, and mitochondrial function through distinct but synergistic mechanisms.

SLU-PP-332 Overview

SLU-PP-332 selectively binds to the orphan nuclear receptors ERRα, ERRβ, and ERRγ, which regulate genes linked to energy metabolism in high-demand tissues such as skeletal muscle, liver, heart, and brain. Upon receptor activation, SLU-PP-332 modulates key metabolic pathways:

• Mitochondrial Biogenesis
  Activates transcription of mitochondrial genes and increases oxidative phosphorylation capacity.

• Fatty Acid Metabolism
  Enhances fatty acid uptake and β-oxidation, promoting lipid utilization as a primary energy source.

• Glucose Metabolism
  Regulates transporters and kinases involved in glucose uptake and metabolism.

• Exercise-Mimetic Effects
  Induces adaptations seen with endurance training, such as shifts in muscle fiber composition and improved aerobic capacity.

BAM15 Overview

BAM15 is a protonophore mitochondrial uncoupler that increases energy expenditure independently of physical activity or food intake. It acts by dissipating the proton gradient across the mitochondrial inner membrane, leading to enhanced metabolic rate and thermogenesis without elevating core body temperature.

Key effects include:

• Enhanced Energy Expenditure
  Promotes caloric burn via inefficient ATP production, leading to a net increase in oxygen consumption.

• Reduced Fat Mass
  Demonstrated reductions in adiposity in animal models of diet-induced obesity.

• Improved Metabolic Health
  Associated with improved insulin sensitivity, glucose tolerance, and hepatic lipid profiles.

• Minimal Impact on Appetite
  Increases basal metabolic rate without stimulating hunger or hyperphagia.

Key Research Highlights of the SLU-PP-332 + BAM15 Combination

Preclinical data and theoretical modeling suggest this combination may:

• Amplify mitochondrial activity and density via distinct mechanisms (genetic and bioenergetic).

• Enhance fat oxidation and glucose handling more effectively than either compound alone.

• Improve aerobic endurance, energy expenditure, and metabolic flexibility.

• Show potential synergy in treating models of obesity, insulin resistance, and mitochondrial dysfunction.

Pharmacokinetics & Distribution

• SLU-PP-332 exhibits moderate oral bioavailability with distribution to metabolically active tissues. Metabolism is primarily hepatic.

• BAM15 demonstrates systemic availability and rapid mitochondrial accumulation, with metabolism likely involving liver enzymes.

Certificate of Analysis (COA)

Technical Specifications

Research Use Only

This product is intended exclusively for laboratory research and in vitro or in vivo preclinical studies. It is not approved for human or veterinary use, nor for diagnostic, therapeutic, or cosmetic purposes. Mislabeling, resale, or misuse of this product as a dietary supplement or pharmaceutical is strictly prohibited.